Expression of class III β-tubulin in malignant epithelial tumours: An immunohistochemical study using TU-20 and TuJ-1 antibodies

Folia Histochemica et Cytobiologica

Volumn 45, Issue 1, 2007, Pages 41-45

  Jirásek, Tomáš ^a   Písaříková, Eva ^a   Viklický, Vladimír ^b   Mandys, Válav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

Carcinomas; Class III tubulin; TU 20; TuJ 1

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TU 20; MONOCLONAL ANTIBODY TUJ 1; PACLITAXEL; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANUS CARCINOMA; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; ESOPHAGUS CARCINOMA; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PAPILLARY CARCINOMA; PREDICTION; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SIGNET RING CARCINOMA; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; TUMOR DIFFERENTIATION; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA;

EID: 33947243491     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Draberova E, Lukas Z, Ivanyi D, Viklicky V, Draber P. Expression of class III beta-tubulin in normal and neoplastic human tissues. Histochem Cell Biol, 1998; 109: 231-239
2. Dumontet C, Jaffrezou JP, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, Sikic BI. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. Bull Cancer, 2004; 91: E81-112
3. Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R, Perol M. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer, 2005; 92: E25-30
4. Easter SS Jr, Ross LS, Frankfurter A. Initial tract formation in the mouse brain. J Neurosci, 1993; 13: 285-299
5. Eberlein-Gonska M, Wiedenmann B, Waldherr R. Synaptophysin, chromogranin A and neuron-specific enolase as tumor markers in neuroendocrine tumors of the gastrointestinal tract and lung. An immunohistochemical study (in German). Pathologe, 1989; 10: 228-233
6. Ferguson RE, Taylor C, Stanley A, Butler E, Joyce A, Harnden P, Patel PM, Selby PJ, Banks RE. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression. Clin Cancer Res, 2005; 11: 3439-3445
7. Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res, 2005; 65: 2397-2405
8. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton, 2003; 56: 45-56
9. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, Monden M, Noguchi S. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res, 2003; 9: 2992-2997
10. Jirasek T, Mandys V, Viklicky V. Expression of class III beta-tubulin in neuroendocrine tumours of gastrointestinal tract. Folia Histochem Cytobiol, 2002; 40: 305-310
11. Katsetos CD, Herman MM, Frankfurter A, Gass P, Collins VP, Walker CC, Rosemberg S, Barnard RO, Rubinstein LJ. Cerebellar desmoplastic medulloblastomas. A further immunohistochemical characterization of the reticulin-free pale islands. Arch Pathol Lab Med, 1989; 113: 1019-1029
12. Katsetos CD, Frankfurter A, Christakos S, Mancall EL, Vlachos IN, Urich H. Differential localization of class III, beta-tubulin isotype and calbindin-D28k defines distinct neuronal types in the developing human cerebellar cortex. J Neuropathol Exp Neurol, 1993; 52: 655-666
13. Katsetos CD, Kontogeorgos G, Geddes JF, Herman MM, Tsimara-Papastamatiou H, Yu Y, Sakkas LI, Tsokos M, Patchefsky AS, Ehya H, Cooper HS, Provencio J, Spano AJ, Frankfurter A. Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med, 2000; 124: 535-544
14. Katsetos CD, Del VL, Geddes JF, Aldape K, Boyd JC, Legido A, Khalili K, Perentes E, Mork SJ. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/ 19q status. J Neuropathol Exp Neurol, 2002; 61: 307-320
15. Katsetos CD, Herman MM, Mork SJ. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton, 2003; 55: 77-96
16. Katsetos CD, Legido A, Perentes E, Mork SJ. Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol, 2003; 18: 851-866
17. Kukharskyy V, Sulimenko V, Macurek L, Sulimenko T, Draberova E, Draber P. Complexes of gamma-tubulin with nonreceptor protein tyrosine kinases Src and Fyn in differentiating P19 embryonal carcinoma cells. Exp Cell Res, 2004; 298: 218-228
18. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol, 2005; 6: 229-239
19. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res, 2005; 11: 298-305
20. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, Schittulli F, Lorusso V. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol, 2005; 16 Suppl 4: iv14-iv19
21. Seve P, Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anti-Cancer Agents, 2005; 5: 73-88
22. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J, 2005; 19: 1299-1301
23. Sullivan KF. Structure and utilization of tubulin isotypes. Annu Rev Cell Biol, 1988; 4: 687-716
24. Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, Haber M, Kavallaris M. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol, 2003; 10: 597-607
25. Wojtowicz A, Szoltys M, Bilinska B. Localization of alpha-tubulin in the rat cumulus oophorus before and during pre-ovulatory ovulatory expansion. Folia Histochem Cytobiol, 2001; 39: 263-267